EyeGate’s EGP-437 Misses Primary Endpoint in Phase III Trial for Anterior Uveitis

September 7, 2018: By Joan McKenna

EyeGate Pharmaceuticals announced Sept. 4 that its candidate for non-infectious anterior segment uveitis failed to show noninferiority to the control group in a Phase III trial.

EGP-437 is a novel formulation of dexamethasone phosphate, delivered to the eye iontophoretically using the company’s EyeGate II Delivery System.

The primary endpoint was the proportion of subjects with an anterior cell count of zero (a sign of diminished inflammation) at Day 14. The control group received prednisolone acetate ophthalmic solution.

EyeGate noted that EGP-437 did show clinical efficacy in the trial.

The Waltham, Massachusetts, company also is developing an Ocular Bandage Gel (OBG) product for corneal surface damage and is enrolling patients in studies for photorefractive keratectomy and punctate epitheliopathy, with topline results expected in Q4-2018. The company said it may shift its focus to the OBG this program.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

Carl Zeiss Meditec Announces Milestone of 1.5 Million SMILE Procedures

Heidelberg Gains US Clearance for OCT Angiography Module

ASCRS Convenes Task Force to Study CyPass Data, Make Recommendations

Bascom Palmer Treats First US Patient in Nightstar’s Trial for X-Linked Retinitis Pigmentosa

First Patient Treated in Allotex’ Trial for Allogenic Refractive Lenticules for Presbyopia

Bausch + Lomb Announces Positive Results for Loteprednol Etabonate Gel

LumiThera Set to Launch Valeda Light Delivery System for Dry AMD

Kodiak Sciences Names Jason Ehrlich, MD, PhD, Chief Medical Officer

Second Sight Receives $1.6 Million Grant from NIH to Support Orion Program

Regeneron to Invest $800 Million in New York Campus

American Women Raise Funds for Nepal Mission to Reduce Corneal Blindness

Ziemer to Add Lenticule Extraction Capabilities to LDV Z8

Stealth BioTherapeutics Raises $100 Million in Support of Elamipretide for Dry AMD

STAAR Gains US Approval of Visian Toric ICL

Sun Pharma, SPARC Announce FDA Approval for Xelpros for Open-Angle Glaucoma, Ocular Hypertension

FDA Will Review Regeneron’s Submission to Expand Eylea’s Labeling to All DR Patients

Alcon Will Locate Headquarters in Switzerland

Kodiak Sciences Files for $100 Million IPO

Iridex Announces $10 Million Public Offering

Oxford BioMedica Expands Capacity with New Facility

Coming soon

2018 Ophthalmic Deals Book: Venture Funding, Commercial Equity, and Business/Technology Sales